#MakeYourMark with a personalised gift for your loved one.
Cure Cancer are delighted to partner with Australian premium leather goods house MAISON de SABRÉ, who embody the art of personalised leather accessories with a timeless spirit. Design innovation meets heritage craftsmanship in their signature collection of cases, wallets, clutches and pocket accessories.
MAISON de SABRÉ are now donating 10% of every purchase made by Cure Cancer supporters to fund the ground-breaking research of Dr Laurence Cheung.
Simply use the code curecancer at checkout.
MAISON de SABRÉ have launched an exclusive Make Your Mark limited edition Phone Case to mark the partnership with Cure Cancer. Championing individual empowerment, the Make Your Mark Foundation is an inspiring new initiative from the brand, embodying a drive to give back to the community through the process of charity alignment and global support networks. We are delighted to have you as part of this exciting new journey.
THE Make Your Mark Case
Card Holder
Mini Tote
Phone Cases
Card case
Pocket bifold
Airpod Case
Zip Wallets
Clutches
Slim Bifold
The Story behind our partnership
Following their father’s leukaemia diagnosis in 2017, brothers Omar and Zane Sabre launched MAISON de SABRÉ, a luxury brand specialising in monogrammed leather goods to help fund Zane’s university studies. Having achieved incredible success since its launch, the brothers are now in a position to ‘give back’. Although their father has thankfully made a good recovery, Omar and Zane are committed to supporting research into blood cancers.
Leukaemia accounts for close to 2,000 deaths in Australia every year and affects men, women and children. Over 4,500 people are diagnosed with leukaemia in Australia every year.
The money raised from the partnership will support the work of Dr Laurence Cheung.
Based at the WA Telethon Kids Institute, Dr Cheung’s research focuses on acute lymphoblastic leukaemia (ALL), the most common form of blood cancer in children. Improvements in therapy over the past sixty years have seen cure rates improve to more than 90%, but several high-risk genetic patient subgroups have much poorer outcomes. Some of these children have less than a 40% chance of survival.
Better therapies for high-risk patients are desperately needed. I believe a combined approach, targeting both cancer cells and surrounding cells, will be an effective therapeutic strategy to treat patients. I am incredibly grateful to MAISON de SABRÉ for committing to support this important work. Together, I hope we can improve the outlook for children with ALL.